Distribution of ovarian cancer recurrence following intravenous (IV) and intraperitoneal (IP) adjuvant chemotherapy after upfront cytoreductive surgery

Vargas, Roberto

170 - Poster Session A
Distribution of ovarian cancer recurrence following intravenous (IV) and intraperitoneal (IP) adjuvant chemotherapy after upfront cytoreductive surgery

Saturday, March 22, 2014: 6:45 PM

West Exhibit Hall (Tampa Convention Center)

R. Vargas¹, J. A. Rauh-Hain², K. M. Esselen³, N. S. Horowitz⁴, J. O. Schorge², M. G. Del Carmen², S. M. Campos⁵ and W. B. Growdon⁶
¹Massachusetts General Hospital/Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital/Harvard University, Boston, MA, ³Brigham and Women's Hospital/Harvard University, Boston, MA, ⁴Harvard University, Boston, MA, ⁵Dana Farber Cancer Center, Boston, MA, ⁶Massachusetts General Hospital, Boston, MA

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

170 - Poster Session A
Distribution of ovarian cancer recurrence following intravenous (IV) and intraperitoneal (IP) adjuvant chemotherapy after upfront cytoreductive surgery

170 - Poster Session A Distribution of ovarian cancer recurrence following intravenous (IV) and intraperitoneal (IP) adjuvant chemotherapy after upfront cytoreductive surgery

170 - Poster Session A
Distribution of ovarian cancer recurrence following intravenous (IV) and intraperitoneal (IP) adjuvant chemotherapy after upfront cytoreductive surgery